BOTOX® in the Treatment of Crow's Feet Lines in China

Study Identifier
191622-113
CT.gov Identifier
NCT02195687
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Toxins
    • Study Drug
  • botulinum toxin Type A
  • Normal Saline
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Moderate to severe Crow's Feet Lines.
    Exclusion Criteria:
    * Current or previous treatment with botulinum toxin of any serotype for any condition within the last year * Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis * Facial laser or light treatment, microdermabrasion or chemical peels within 3 months * Radio frequency laser treatments, phototherapy, blepharoplasty, brow-lift or related procedure, permanent make-up, oral retinoid therapy or treatment with non-permanent soft tissue fillers within 1 year * Any medium-depth or deep facial peels within 5 years * Periorbital surgery, face-lift, mid facial or periorbital treatment with permanent soft tissue fillers, synthetic implants or autologous fat transplant.

    Protocol Summary

    This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared with placebo in patients with moderate to severe crow's feet lines (lateral canthal lines).

    Study Locations

    Location
    Status
    Location
    Beijing, China
    Status
    Not applicable